Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial
Uro-Oncology
Related content
Uro-Oncology
Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of comparative studies
Prostate Cancer Prostatic Dis
Falagario UG, Pellegrino F, Fanelli A, Guzzi F, Bartoletti R, Cash H, Pavlovich C, Emberton M, Carrieri G, Giannarini G
doi: 10.1038/s41391-024-00827-x
Uro-Oncology
PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer
Eur Urol
Englman C, Maffei D, Allen C, Kirkham A, Albertsen P, Kasivisvanathan V, Baroni RH, Briganti A, De Visschere P, Dickinson L, Gómez Rivas J, Haider MA, Kesch C, Loeb S, Macura KJ, Margolis D, Mitra AM, Padhani AR, Panebianco V, Pinto PA, Ploussard G, Puech P, Purysko AS, Radtke JP, Rannikko A, Rastinehad A, Renard-Penna R, Sanguedolce F, Schimmöller L, Schoots IG, Shariat SF, Schieda N, Tempany CM, Turkbey B, Valerio M, Villers A, Walz J, Barrett T, Giganti F, Moore CM
doi: 10.1016/j.eururo.2024.03.014
Uro-Oncology
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Eur Urol
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR
doi: 10.1016/j.eururo.2024.03.036
Further Publications Urology
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials
Prostate Cancer Prostatic Dis
Shelan M, Achard V, Appiagyei F, Mose L, Zilli T, Fankhauser CD, Zamboglou C, Mohamad O, Aebersold DM, Cathomas R
doi: 10.1038/s41391-024-00829-9
COMMENTED
Uro-Oncology
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
JAMA Oncol
Tilki D, Chen MH, Wu J, Huland H, Graefen M, Trock BJ, Han M, D'Amico AV
doi: 10.1001/jamaoncol.2025.0110
Further Publications Urology
The 'Prostate Embolisation AS first-line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial' (P-EASY ADVANCE): a randomised controlled trial of prostate embolisation vs medication for BPH
BJU Int
Brown N, Kiosoglous A, Castree S, Firouzmand S, McBean R, Walker DG, Wallace S, Kua B, Gianduzzo T, Esler RC, Campbell P, Schoeman J, Yaxley J
doi: 10.1111/bju.16479
Benign Prostatic Hyperplasia (BPH)
Do Prostate Imaging-Reporting and Data System (PIRADS) lesions predict holmium laser enucleation of prostate outcomes?
Prostate
Tsai K, Xu P, Guo J, Dean N, Khondakar N, Michael J, Neill C, Krambeck A
doi: 10.1002/pros.24771
Benign Prostatic Hyperplasia (BPH)
Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
Prostate
Jirásko M, Viták R, Pecen L, Pinkeová A, Tkáč J, Bertók T, Bergman N, Kučera R
doi: 10.1002/pros.24801
Further Publications Urology
Safety and Efficacy of Intra-Prostatic Injection of Betamethasone for Refractory Chronic Nonbacterial Prostatitis: A Prospective Cohort Clinical Study
Prostate
Abdelaziz AY, Kishk MA, Meshref A, Elfayomy H, Rammah A, Abozamel AH
doi: 10.1002/pros.24819